Journal of Population Therapeutics & Clinical Pharmacology

RESEARCH ARTICLE
DOI: 10.53555/r9cnps86

A REVIEW ON AI DRIVEN DRUG DISCOVERY

Anuradha Nerella[1]*, Dr. D Narendra[2], Devi Sai Santhoshi Sravya[3], Bindu Kalyani[4], Yagna Sri[5], Sravani Naga Sri[6], Neeraja[7]

[1]Assistant Professor, Department of Pharmaceutics, VJ's college of Pharmacy, Rajahmundry, Andhra Pradesh - India.
[2]Principal & Professor, Department of Pharmaceutical analysis, VJ's college of Pharmacy, Rajahmundry, Andhra Pradesh – India.
[3]Student, Department of Pharmacy, VJ's college of Pharmacy, Rajahmundry, Andhra Pradesh – India.
[4]Student, Department of Pharmacy, VJ's college of Pharmacy, Rajahmundry, Andhra Pradesh – India.
[5]Student, Department of Pharmacy, VJ's college of Pharmacy, Rajahmundry, Andhra Pradesh – India.
[6]Student, Department of Pharmacy, VJ's college of Pharmacy, Rajahmundry, Andhra Pradesh – India.
[7]Student, Department of Pharmacy, VJ's college of Pharmacy, Rajahmundry, Andhra Pradesh – India.

ABSTRACT:
Artificial intelligence is the present emerging technology even in the discovery of medicines. AI helps to speed up the work, reduce the cost of time, and gives more accurate decisions. In recent years few AI tools for drug development have been used. Insilico (chemistry 42) is designed to target a disease and design a new drug molecule, having already reached the advanced testing stages. SyntheX was pioneering intracellular drug discovery by using the synthetic biology and DNA-encoded libraries, which identify the small molecules and undruggable proteins. BioNtech and Instadeep have been created a lab which have been focused on the immune based treatment BioNtech brought Instadeep to involve deeper into its drug development process. NVIDIA clara Discovery offers high-powered tools to the researchers to stimulate the molecules and to analyze the data for brisk drug discovery and more scalable.

Keywords: Drug discovery, Insilico, Synthace, Disease, Researchers, BioNtech, Immune based treatment.

INTRODUCTION:

The process of drug discovery has historically been a long, expensive, and uncertain journey. Developing a single therapeutic compound from initial concept to market approval typically spans 10 to 15 years and costs over $2 billion USD. This timeline includes multiple stages target identification, lead compound screening, preclinical testing, and three phases of clinical trials each fraught with high attrition rates and scientific complexity. Despite advances in molecular biology, genomics, and high-throughput screening, the pharmaceutical industry continues to face significant challenges in reducing development time and improving success rates.[1]

In recent years, Artificial Intelligence (AI) has emerged as a transformative force in pharmaceutical research and development. By leveraging machine learning algorithms, deep neural networks, and generative models, AI offers the potential to revolutionize every stage of the drug discovery pipeline. From identifying novel biological targets and predicting protein structures to designing drug-like molecules and optimizing clinical trial protocols, AI enables faster, more accurate, and cost-effective decision-making. The integration of AI into drug discovery not only accelerates timelines but also enhances precision, reduces experimental burden, and opens new avenues for personalized medicine.[2]

· Insilico Medicine, a pioneer in generative AI for end-to-end drug development, has successfully advanced an AI-designed molecule into Phase II clinical trials.

· InstaDeep, acquired by BioNTech, specializes in protein modeling and molecular simulation, supporting mRNA vaccine development and cancer immunotherapy.

· SyntheX, a biotech innovator, uses AI to identify synthetic lethal interactions and design molecular glues for oncology applications.

· BioNTech, known for its COVID-19 mRNA vaccine, is building a supercomputing infrastructure to scale AI across its therapeutic pipeline.

· NVIDIA Clara, a healthcare AI platform, provides the computational backbone for many of these innovations, enabling high-performance modeling, federated learning, and privacy preserving data analysis.[3]

ROLE OF AI IN DRUG DISCOVERY:

Artificial Intelligence (AI) has become an indispensable tool in modern drug discovery, offering unprecedented speed, accuracy, and scalability across the entire pharmaceutical development pipeline. Traditional methods rely heavily on trial-and-error experimentation, which is both time-consuming and resource-intensive. In contrast, AI leverages computational models trained on vast biological datasets to make predictive, data-driven decisions that streamline the discovery process.[4]

Applications of AI in Drug Discovery

- Target Identification AI algorithms analyze genomic, proteomic, and transcriptomic data to identify disease-relevant biological targets. Machine learning models can detect subtle patterns and associations that may be missed by human researchers, enabling the discovery of novel therapeutic targets with high precision.
- Molecule Generative AI models, such as variational autoencoders and generative adversarial networks (GANs), are used to design new drug-like molecules. These models can generate thousands of chemical structures that meet specific pharmacological criteria, significantly reducing the time required for lead compound identification.

Technologies Used in AI-Driven Drug Discovery

- Deep Learning Deep Neural Networks are used for image analysis, molecular property prediction, and protein structure modeling. These models excel at handling complex, high-dimensional data and are foundational to many AI platforms in drug discovery.
- Reinforcement Learning This technique is used to optimize molecular design by rewarding models for generating compounds with desirable properties. It enables iterative improvement and exploration of chemical space.

ADVANTAGES AND DISADVANTAGES:

Advantages of ai in drug discovery:

Reduces the need for extensive lab testing by simulating drug behavior.

BioNTech integrates AI with mRNA platforms to streamline vaccine development and reduce trial costs.

AI helps pinpoint disease-related genes and proteins more accurately.

SyntheX applies AI to discover novel protein interactions for targeted therapies.

AI predicts drug safety, efficacy, and side effects before clinical trials.

NVIDIA Clara *Discovery* uses high-performance computing to simulate molecular interactions.
AI tailor's treatments to individual genetic profiles, improving outcomes.
InstaDeep uses reinforcement learning to optimize personalized drug regimens.

Disadvantages of AI in Drug Discovery
AI models rely on large, clean datasets, which are often incomplete or biased.
Poor data can lead to inaccurate predictions or missed therapeutic targets.
Many AI systems operate as "black boxes," making it hard to explain how decisions are made.
This lack of interpretability can hinder regulatory approval and clinical trust.
Drug regulators require rigorous validation, and AI-generated results may not meet traditional standards.
Integrating AI into existing regulatory frameworks remains a slow process.
AI must not complement lab experiments and clinical trials.
Companies like BioNTech and Insilico combine AI with wet-lab validation to ensure reliability.

INSILICO MEDICINE – OVERVIEW AND CONTRIBUTIONS:

Insilico Medicine is a pioneering biotechnology company that has gained global recognition for its innovative use of artificial intelligence in drug discovery. Founded in 2014, the company has developed a comprehensive AI platform Pharma.AI which integrates multiple stages of the drug development process, including target identification, molecule generation, and clinical trial prediction. Insilico's mission is to accelerate the discovery of novel therapeutics by leveraging deep learning and generative models to reduce time, cost, and risk.[5]

At the core of Insilico's technology is its ability to generate drug-like molecules using generative adversarial networks (GANs) and reinforcement learning algorithms. These models are trained in vast chemical and biological datasets, enabling the platform to design compounds with optimized pharmacokinetic and pharmacodynamic properties. The AI system also predicts the biological activity and toxicity of these molecules, allowing researchers to prioritize the most promising candidates for experimental validation.[6]



[7]

Fig.1- AI powered drug discovery pipeline by Insilico medicine.

INSTADEEP – OVERVIEW AND APPLICATIONS:

InstaDeep is a cutting-edge AI company specializing in decision-making systems and biological modeling, with a strong focus on drug discovery and protein engineering. Founded in 2014 and

headquartered in London, InstaDeep quickly gained recognition for its innovative use of deep reinforcement learning and computational biology. In 2023, the company was acquired by BioNTech, a global leader in mRNA-based therapeutics, marking a strategic move to integrate AI into BioNTech's drug development pipeline.[8]

InstaDeep's flagship platform, DeepChain, is designed to accelerate protein design and molecular simulation. DeepChain uses advanced machine learning models to predict protein folding, optimize binding affinities, and simulate molecular interactions. These capabilities are particularly valuable in the development of biologics, vaccines, and targeted therapies, where understanding protein behavior is critical.[9]

[10]

Fig.2- Instadeep in Pharma sector.

BIONTECH – AI INTEGRATION AND STRATEGIC EXPANSION:

BioNTech SE, a German biotechnology company founded in 2008, gained global prominence for its development of the first approved mRNA-based COVID-19 vaccine in partnership with Pfizer. While BioNTech is best known for its work in infectious diseases, the company has a broader mission: to harness cutting-edge technologies including artificial intelligence (AI) to revolutionize the development of personalized immunotherapies for cancer and other serious diseases.[11]

BioNTech also applies AI to clinical trial optimization, using predictive models to simulate trial outcomes, stratify patient populations, and identify biomarkers for response. This leads to more efficient trials with higher success rates and reduced costs. Additionally, AI helps the company monitor real-world data and post-market surveillance, ensuring the safety and efficacy of its therapies.[12]



13

Fig.3- BioNtech in building tomorrow's Personalized precision medicine.

SYNTHEX – AI-GUIDED SYNTHETIC LETHALITY AND ONCOLOGY INNOVATION:

SyntheX, a San Francisco-based biotechnology company, is at the forefront of applying artificial intelligence to the discovery of novel cancer therapeutics. Founded with a mission to exploit synthetic lethality a concept where the simultaneous disruption of two genes leads to cell death, while disruption of either alone does not SyntheX uses AI to identify and target these vulnerabilities in cancer cells. This approach enables the development of highly selective drugs that kill tumor cells while sparing healthy tissue.[14]

One of the company's key innovations is the development of molecular glues small molecules that induce interactions between proteins that do not naturally bind. These glues can redirect cellular machinery to degrade disease-causing proteins or activate tumor suppressors. SyntheX uses AI to model protein-protein interactions and predict the structural features required for glue-like behavior, significantly accelerating the design and optimization of these compounds.

In addition to molecular glues, SyntheX is exploring targeted protein degraders, which harness the cell's own degradation pathways to eliminate harmful proteins. AI plays a critical role in identifying degron motifs, predicting binding affinities, and optimizing linker chemistry. These capabilities enable the rapid development of next-generation therapeutics with improved efficacy and reduced toxicity.[15]



16

Fig.4- SyntheX Overview.

NVIDIA CLARA – AI INFRASTRUCTURE FOR DRUG DISCOVERY:

NVIDIA Clara is a comprehensive AI platform developed by NVIDIA to support healthcare and life sciences applications. While NVIDIA is best known for its graphics processing units (GPUs), the company has made significant strides in enabling AI-driven innovation across industries. Clara is specifically designed to accelerate workflows in medical imaging, genomics, and drug discovery by providing high-performance computing infrastructure and advanced AI frameworks.[17]

In addition to drug discovery, Clara supports protein structure prediction, compound screening, and clinical trial simulation. Its integration with tools like AlphaFold and ESMFold allows researchers to model protein folding with high accuracy, aiding in the identification of druggable sites and binding affinities. Clara also facilitates real-time visualization and analysis, enabling researchers to interact with molecular data in intuitive ways.

In addition to drug discovery, Clara supports protein structure prediction, compound screening, and clinical trial simulation. Its integration with tools like AlphaFold and ESMFold allows researchers to model protein folding with high accuracy, aiding in the identification of druggable sites and binding affinities. Clara also facilitates real-time visualization and analysis, enabling researchers to interact with molecular data in intuitive ways.[18]



19

Fig.5- NVIDIA Clara Infrastructure for drug discovery.

Future Perspectives in AI-Driven Drug Discovery:

As artificial intelligence continues to evolve, its role in drug discovery is expected to expand dramatically, reshaping the pharmaceutical landscape in ways that were once considered science fiction. The convergence of AI with other emerging technologies such as quantum computing, synthetic biology, and multi-omics integration promises to unlock new frontiers in precision medicine, accelerate therapeutic innovation, and democratize access to healthcare.[20]

21

Fig.6- Future Perspectives in AI-Driven Drug Discovery.

In the realm of clinical trials, AI will enable real-time monitoring, adaptive trial designs, and predictive modeling of patient outcomes. These capabilities will reduce trial durations, improve enrollment efficiency, and increase the likelihood of regulatory approval. AI-driven virtual trial may also emerge, allowing researchers to simulate trial scenarios before launching them in the real world.[22]

Platform	Focus Area	Key Technologies	Notable Milestone
Insilico Medicine	End-to-end drug discovery	Generative AI, GANs, RL	Phase II trial of AI-designed IPF drug (INS018_055)
InstaDeep	Protein modeling & simulation	DeepChain, LLMs, RL	Acquisition by BioNTech; integration into mRNA pipeline
BioNTech	mRNA-based therapeutics	Supercomputing (Kyber), ML	Personalized cancer vaccines using AI-predicted neoantigens
SyntheX	Synthetic lethality in oncology	CRISPR screens, ML, molecular glues	AI-designed protein degraders and glue molecules
NVIDIA Clara	AI infrastructure for life sciences	GPUs, federated learning, Clara Discovery	Backbone for Insilico and BioNTech AI workflows

Table-1: AI platforms and technologies, Notable milestones in focusing areas.

CONCLUSION:

The integration of artificial intelligence into drug discovery marks a paradigm shift in pharmaceutical research and development. By automating complex tasks, accelerating timelines, and enhancing predictive accuracy, AI is transforming how therapeutics are discovered, optimized, and delivered to patients. Platforms such as Insilico Medicine, InstaDeep, SyntheX, BioNTech, and NVIDIA Clara exemplify the diverse and powerful applications of AI—from generative molecule design and protein modeling to infrastructure support and personalized medicine.

The integration of artificial intelligence into drug discovery marks a paradigm shift in pharmaceutical research and development. By automating complex tasks, accelerating timelines, and enhancing predictive accuracy, AI is transforming how therapeutics are discovered, optimized, and delivered to patients. Platforms such as Insilico Medicine, InstaDeep, SyntheX, BioNTech, and NVIDIA Clara exemplify the diverse and powerful applications of AI—from generative molecule design and protein modeling to infrastructure support and personalized medicine.

References:

1. SandboxAQ. AI Models Enhance the Drug Discovery Portfolio [Internet]. Genetic Engineering & Biotechnology News; 2025 Nov 1 [cited 2025 Nov 5]. Available from: https://www.genengnews.com/topics/artificial-intelligence/ai-models-enhance-the-drug-discovery-portfolio/
2. Platform Executive. AI in Drug Discovery: Speeding Up Development and Reducing Costs (2025–2030) [Internet]. 2025 Sep 17 [cited 2025 Nov 5]. Available from: https://www.platformexecutive.com/insight/health-care-research/ai-in-drug-discovery/
3. BestAI Blog. How AI is Slashing Drug Discovery and Development Costs: A New Era in Pharmaceutical Innovation [Internet]. 2025 May 19 [cited 2025 Nov 5]. Available from: https://blog.bestai.com/how-ai-is-slashing-drug-discovery-and-development-costs-a-new-era-in-pharmaceutical-innovation/
4. Ocana A, Pandiella A, Privat C, Bravo I, Luengo-Oroz M, Amir E, et al. Integrating artificial intelligence in drug discovery and early drug development: a transformative approach. *Biomark Res* [Internet]. 2025 Mar 14 [cited 2025 Nov 5];13(45). Available from: https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-025-00758-2
5. Insilico Medicine. Main Insilico Medicine [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://insilico.com/

6. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nat Biotechnol* [Internet]. 2019 Jan [cited 2025 Nov 5];37(1):103–6. Available from: https://www.nature.com/articles/s41587-018-0005-z
7. Insilico Medicine. Insilico Medicine Harnesses AI to Break the 12-Year Drug Development Curse [Internet]. GeneOnline; 2025 Jun 17 [cited 2025 Nov 5]. Available from: https://www.geneonline.com/insilico-medicine-harnesses-ai-to-break-the-12%E2%80%91year-drug-development-curse/
8. BioNTech SE. BioNTech Completes Acquisition of InstaDeep [Internet]. InstaDeep; 2023 Jul 31 [cited 2025 Nov 5]. Available from: https://instadeep.com/2023/07/biontech-completes-acquisition-of-instadeep/
9. InstaDeep. DeepChain Accelerate R&D and boost innovation and efficiency [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://deepchain.bio/
10. InstaDeep. InstaDeep in Pharma [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://instadeep.com/pharma/
11. BioNTech SE. BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update [Internet]. 2025 Nov 3 [cited 2025 Nov 5]. Available from: https://markets.businessinsider.com/news/stocks/biontech-announces-third-quarter-2025-financial-results-and-corporate-update-1035476282
12. Research and Markets. AI-Powered Clinical Trial Site Feasibility Research Report 2025: Market to Reach $3.55 Billion by 2029 [Internet]. GlobeNewswire; 2025 Nov 4 [cited 2025 Nov 5]. Available from: https://www.globenewswire.com/news-release/2025/11/04/3180613/28124/en/AI-Powered-Clinical-Trial-Site-Feasibility-Research-Report-2025-Market-to-Reach-3-55-Billion-by-2029-Fueled-by-Accelerated-Trial-Recruitment-Decentralized-Study-Models-and-Advanced.html
13. McKinsey & Company. Faster, smarter trials: Modernizing biopharma's R&D IT applications [Internet]. 2025 Feb 13 [cited 2025 Nov 5]. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/faster-smarter-trials-modernizing-biopharmas-r-and-d-it-applications
14. SyntheX. About Us SyntheX Therapeutics [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://www.synthexlabs.com/about/
15. Gainza P. AI Applications for Molecular Glue Degraders: From Degron Discovery to in silico Screening [Internet]. Targeted Protein Degradation Summit; 2022 Oct 26 [cited 2025 Nov 5]. Available from: https://ir.monterosatx.com/static-files/8806793a-99fb-4df8-8eb7-3785b39cf210
16. Plescia J. Degrader linker design for targeted protein degradation [Internet]. Cresset Group; 2024 May 14 [cited 2025 Nov 5]. Available from: https://cresset-group.com/science/science-resources/degrader-linker-design-targeted-protein-degradation/
17. NVIDIA. BioPharma Solutions for AI-Accelerated Drug Discovery [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://www.nvidia.com/en-us/industries/healthcare-life-sciences/drug-discovery/
18. NVIDIA Corporation. Protein Structure Prediction With Predictive AI [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://www.nvidia.com/en-gb/use-cases/protein-structure-prediction-with-predictive-ai/
19. NVIDIA Corporation. Protein Structure Prediction With Predictive AI [Internet]. 2025 [cited 2025 Nov 5]. Available from: https://www.nvidia.com/en-gb/use-cases/protein-structure-prediction-with-predictive-ai/
20. McKinsey & Company. The quantum revolution in pharma: Faster, smarter, and more precise [Internet]. 2025 Aug 25 [cited 2025 Nov 5]. Available from: https://www.mckinsey.com/industries/life-sciences/our-insights/the-quantum-revolution-in-pharma-faster-smarter-and-more-precise

21. Kipu Quantum GmbH. Kipu Quantum at AI in Drug Discovery 2025 [Internet]. 2025 Mar 24 [cited 2025 Nov 5]. Available from: https://kipu-quantum.com/knowledge-hub/blog/kipu-quantum-at-ai-in-drug-discovery-2025/
22. Shukla R, Bahl A. Transforming Clinical Trials with AI-Driven Protocol Optimization and Next-Gen Statistical Programming [Internet]. PHUSE US; 2025 [cited 2025 Nov 5]. Available from: https://www.lexjansen.com/phuse-us/2025/et/PAP_ET15.pdf